AL
ALSGD.PA Spineguard
- Market cap
- EUR 8.41M
- P/E
- -
- P/B
- 1.88x
- ROE
- -109.4%
- Dividend yield
- -
- Fundamental score
- 0.8/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ALSGD.PA undervalued?
Graham numberThe Graham number of Spineguard cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Spineguard fundamental analysis
3 of 11 checks passedROE 0/2
Negative ROE (-46.97%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.
ROA 0/2
The stock's ROA (-33.46%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.
PBV 1/2
The stock's PBV ratio (1.35x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.
DER 1/2
The stock maintains a fair debt to equity ratio (74%), indicating a reasonable balance between the money it owes and the ownership it possesses.
Revenue Growth 0/2
Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.
Net Profit Growth 0/2
Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.
Assets Growth 0/2
Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.
Graham Number 1/1
Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.
Dividend Growth 0/2
The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.
Dividend 0/2
Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.
Buffet Intrinsic Value 0/1
The company's stock presents a potential concern as it appears overvalued (-1) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Spineguard stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Spineguard
SpineGuard SA provides designs, develops, and markets medical devices in the United States, Europe, Latin America, Asia Pacific, and the Middle East. The company offers PediGuard drilling instruments comprising straight, curved, cannulated, PsiFGuard, and threaded PediGuard products. It also provides DSG Connect app that provides surgeons real time visualization of the audio feedback from the DSG Technology during pedicle drillings to ease the signal interpretation. The comp…
Full company profileSpineguard financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Spineguard annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.46M | 8.17M | 7.58M | 6.83M | 4.85M | 4.41M | 5.60M | 4.31M | 4.65M | 3.76M | 5.80M |
| Gross Profit | 6.35M | 6.95M | 6.55M | 5.77M | 3.87M | 3.43M | 4.52M | 3.38M | 3.63M | 2.96M | 3.55M |
| Operating Income | -3.63M | -2.55M | -1.07M | -311K | -1.84M | -1.35M | -1.66M | -3.98M | -3.06M | -1.66M | -4.71M |
| EBITDA | -3.20M | -3.01M | -989K | 61.1K | -1.59M | -812K | -1.27M | -3.50M | -2.75M | -1.40M | -4.16M |
| Net Income | -4.18M | -4.13M | -2.33M | -686K | -2.72M | -1.72M | -2.39M | -4.18M | -3.08M | -2.07M | -4.90M |
| EPS | -0.83 | -0.75 | -0.37 | -0.07 | -0.13 | -0.06 | -0.07 | -0.11 | -0.06 | -0.02 | -0.05 |
| Balance Sheet | |||||||||||
| Total Assets | 9.41M | 8.15M | 7.86M | 8.50M | 8.06M | 11.9M | 11.5M | 11.0M | 8.23M | 8.39M | 8.10M |
| Total Liabilities | 8.22M | 8.36M | 8.35M | 7.90M | 8.07M | 6.85M | 6.36M | 5.00M | 4.33M | 2.92M | 3.62M |
| Shareholders' Equity | 1.19M | -208K | -490K | 592K | -8.93K | 5.05M | 5.14M | 6.03M | 3.90M | 5.47M | 4.48M |
| Cash & Short-term Investments | 1.80M | 1.19M | 1.06M | 1.40M | 1.22M | 5.21M | 4.12M | 3.89M | 719K | 1.72M | 694K |
| Total Debt | 6.00M | 6.23M | 6.07M | 6.08M | 5.64M | 4.47M | 3.83M | 3.09M | 2.51M | 1.46M | 1.40M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -4.03M | -2.51M | -669K | 224K | -949K | -1.16M | -1.78M | -3.65M | -2.35M | -1.04M | -4.35M |
| Capital Expenditure | 56.9K | 42.5K | 47.9K | 77.1K | 197K | 368K | 458K | 167K | 369K | 115K | 16.00 |
| Free Cash Flow | -4.09M | -2.55M | -717K | 147K | -1.15M | -1.87M | -2.24M | -3.82M | -2.72M | -1.16M | -4.35M |
| Ratios | |||||||||||
| ROE | -351.1% | - | - | -115.8% | - | -34.2% | -46.5% | -69.4% | -79.0% | -37.8% | -109.4% |
| ROA | -44.4% | -50.6% | -29.7% | -8.1% | -33.7% | -14.5% | -20.8% | -37.9% | -37.5% | -24.6% | -60.5% |
| Net Profit Margin | -56.0% | -50.5% | -30.8% | -10.0% | -56.0% | -39.2% | -42.7% | -97.0% | -66.3% | -55.0% | -84.6% |
| Debt to Equity | 5.04x | - | - | 10.28x | - | 0.89x | 0.74x | 0.51x | 0.64x | 0.27x | 0.31x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Spineguard dividends
Spineguard has not paid dividends in the last 9 fiscal years.
Last stock split: 351:337 on Dec 9, 2025.
Who owns Spineguard
- Insiders 2.84%
- Institutions 0.00%
- Public & others 97.16%
- Shares outstanding 96.9M
- Free float 45.5M
Spineguard company profile
- Company name
- Spineguard
- Ticker
- ALSGD.PA
- ISIN
- FR0011464452
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 9
- Fiscal year end
- December
- Address
- 10 Cours Louis Lumiere, Vincennes, France, 94300
- Phone
- 33 1 45 18 45 19
- Website
- spineguard.com
About Spineguard
SpineGuard SA provides designs, develops, and markets medical devices in the United States, Europe, Latin America, Asia Pacific, and the Middle East. The company offers PediGuard drilling instruments comprising straight, curved, cannulated, PsiFGuard, and threaded PediGuard products. It also provides DSG Connect app that provides surgeons real time visualization of the audio feedback from the DSG Technology during pedicle drillings to ease the signal interpretation. The company's products are used in orthopedic robots and dental implantology. SpineGuard SA was incorporated in 2009 and is headquartered in Vincennes, France.
Spineguard management
5- Mr. Pierre JeromeCo-Founder, Chairman of the Board & CEO
- Mr. Stephane BetteCo-Founder, Deputy CEO & Director
- Mr. Maurice Bourlion Ph.D.Co-Inventor & Director
- Ms. Anne-Charlotte MillardChief Financial Officer
- Ms. Patricia LempereurVice President of International Sales & Global Marketing